Cefotiam
| Clinical data | |
|---|---|
| Trade names | Pansporin | 
| AHFS/Drugs.com | International Drug Names | 
| Routes of administration | Intravenous, intramuscular | 
| ATC code | |
| Legal status | |
| Legal status | 
 | 
| Pharmacokinetic data | |
| Bioavailability | 60% (intramuscular) | 
| Protein binding | 40% | 
| Metabolism | Nil | 
| Elimination half-life | Approximately 1 hour | 
| Excretion | Renal | 
| Identifiers | |
| 
 | |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.205.922 | 
| Chemical and physical data | |
| Formula | C18H23N9O4S3 | 
| Molar mass | 525.62 g·mol−1 | 
| 3D model (JSmol) | |
| 
 | |
| 
 | |
| (verify) | |
Cefotiam is a parenteral third-generation cephalosporin antibiotic. It has broad-spectrum activity against Gram-positive and Gram-negative bacteria. As a beta-lactam, its bactericidal activity results from the inhibition of cell wall synthesis via affinity for penicillin-binding proteins.
It was patented in 1973 and approved for medical use in 1981.